Cargando…

How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England

OBJECTIVES: To examine validity of prevalence-based models giving projections of prevalence of diabetes in adults, in England and the UK, and of Markov chain models giving estimates of economic impacts of interventions to prevent type 2 diabetes (T2D). METHODS: Rapid reviews of both types of models....

Descripción completa

Detalles Bibliográficos
Autores principales: Bevan, Gwyn, De Poli, Chiara, Keng, Mi Jun, Raine, Rosalind
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059487/
https://www.ncbi.nlm.nih.gov/pubmed/32132137
http://dx.doi.org/10.1136/bmjopen-2019-033483
_version_ 1783504060576432128
author Bevan, Gwyn
De Poli, Chiara
Keng, Mi Jun
Raine, Rosalind
author_facet Bevan, Gwyn
De Poli, Chiara
Keng, Mi Jun
Raine, Rosalind
author_sort Bevan, Gwyn
collection PubMed
description OBJECTIVES: To examine validity of prevalence-based models giving projections of prevalence of diabetes in adults, in England and the UK, and of Markov chain models giving estimates of economic impacts of interventions to prevent type 2 diabetes (T2D). METHODS: Rapid reviews of both types of models. Estimation of the future prevalence of T2D in England by Markov chain models; and from the trend in the prevalence of diabetes, as reported in the Quality and Outcomes Framework (QOF), estimated by ordinary least squares regression analysis. SETTING: Adult population in England and UK. MAIN OUTCOME MEASURE: Prevalence of T2D in England and UK in 2025. RESULTS: The prevalence-based models reviewed use sample estimates of past prevalence rates by age and sex and projected population changes. Three most recent models, including that of Public Health England (PHE), neither take account of increases in obesity, nor report Confidence Intervals (CIs). The Markov chain models reviewed use transition probabilities between states of risk and death, estimated from various sources. None of their accounts give the full matrix of transition probabilities, and only a minority report tests of validation. Their primary focus is on estimating the ratio of costs to benefits of preventive interventions in those with hyperglycaemia, only one reported estimates of those developing T2D in the absence of a preventive intervention in the general population. Projections of the prevalence of T2D in England in 2025 were (in millions) by PHE, 3.95; from the QOF trend, 4.91 and by two Markov chain models, based on our review, 5.64 and 9.07. CONCLUSIONS: To inform national policies on preventing T2D, governments need validated models, designed to use available data, which estimate the scale of incidence of T2D and survival in the general population, with and without preventive interventions.
format Online
Article
Text
id pubmed-7059487
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70594872020-03-20 How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England Bevan, Gwyn De Poli, Chiara Keng, Mi Jun Raine, Rosalind BMJ Open Diabetes and Endocrinology OBJECTIVES: To examine validity of prevalence-based models giving projections of prevalence of diabetes in adults, in England and the UK, and of Markov chain models giving estimates of economic impacts of interventions to prevent type 2 diabetes (T2D). METHODS: Rapid reviews of both types of models. Estimation of the future prevalence of T2D in England by Markov chain models; and from the trend in the prevalence of diabetes, as reported in the Quality and Outcomes Framework (QOF), estimated by ordinary least squares regression analysis. SETTING: Adult population in England and UK. MAIN OUTCOME MEASURE: Prevalence of T2D in England and UK in 2025. RESULTS: The prevalence-based models reviewed use sample estimates of past prevalence rates by age and sex and projected population changes. Three most recent models, including that of Public Health England (PHE), neither take account of increases in obesity, nor report Confidence Intervals (CIs). The Markov chain models reviewed use transition probabilities between states of risk and death, estimated from various sources. None of their accounts give the full matrix of transition probabilities, and only a minority report tests of validation. Their primary focus is on estimating the ratio of costs to benefits of preventive interventions in those with hyperglycaemia, only one reported estimates of those developing T2D in the absence of a preventive intervention in the general population. Projections of the prevalence of T2D in England in 2025 were (in millions) by PHE, 3.95; from the QOF trend, 4.91 and by two Markov chain models, based on our review, 5.64 and 9.07. CONCLUSIONS: To inform national policies on preventing T2D, governments need validated models, designed to use available data, which estimate the scale of incidence of T2D and survival in the general population, with and without preventive interventions. BMJ Publishing Group 2020-03-03 /pmc/articles/PMC7059487/ /pubmed/32132137 http://dx.doi.org/10.1136/bmjopen-2019-033483 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Diabetes and Endocrinology
Bevan, Gwyn
De Poli, Chiara
Keng, Mi Jun
Raine, Rosalind
How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England
title How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England
title_full How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England
title_fullStr How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England
title_full_unstemmed How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England
title_short How valid are projections of the future prevalence of diabetes? Rapid reviews of prevalence-based and Markov chain models and comparisons of different models’ projections for England
title_sort how valid are projections of the future prevalence of diabetes? rapid reviews of prevalence-based and markov chain models and comparisons of different models’ projections for england
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059487/
https://www.ncbi.nlm.nih.gov/pubmed/32132137
http://dx.doi.org/10.1136/bmjopen-2019-033483
work_keys_str_mv AT bevangwyn howvalidareprojectionsofthefutureprevalenceofdiabetesrapidreviewsofprevalencebasedandmarkovchainmodelsandcomparisonsofdifferentmodelsprojectionsforengland
AT depolichiara howvalidareprojectionsofthefutureprevalenceofdiabetesrapidreviewsofprevalencebasedandmarkovchainmodelsandcomparisonsofdifferentmodelsprojectionsforengland
AT kengmijun howvalidareprojectionsofthefutureprevalenceofdiabetesrapidreviewsofprevalencebasedandmarkovchainmodelsandcomparisonsofdifferentmodelsprojectionsforengland
AT rainerosalind howvalidareprojectionsofthefutureprevalenceofdiabetesrapidreviewsofprevalencebasedandmarkovchainmodelsandcomparisonsofdifferentmodelsprojectionsforengland